BlueRock Therapeutics: Sizing Up The Regenerative Power Of Cells
An Interview With CEO Emile Nuwaysir
• By William Looney
Bayer's novel 2016 joint venture with the venture capital group Versant Ventures has spawned something like a big pharma, new science start-up, with an open mandate to disrupt drug development through generous endowments in the scarce commodities of freedom, time and patience.
Emile Nuwaysir, CEO of BlueRock Therapeutics
In Vivo talks to the CEO of BlueRock Therapeutics, Emile Nuwaysir, the exemplar of this new approach, which Bayer AG is trusting to strengthen its cardiovascular and neurodegenerative portfolio through the hard science of induced cell repair and restoration.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
Karen Rodriguez Lorenc has overseen linvoseltamab's development and subsequent approvals in Europe and the US. She talked to In Vivo about how patient-centric drug development philosophy is core to her leadership, and why she doesn't believe in failure.
In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.